ATE397014T1 - Hiv-peptide, antigene und impfstoffzusammensetzungen - Google Patents

Hiv-peptide, antigene und impfstoffzusammensetzungen

Info

Publication number
ATE397014T1
ATE397014T1 AT00911492T AT00911492T ATE397014T1 AT E397014 T1 ATE397014 T1 AT E397014T1 AT 00911492 T AT00911492 T AT 00911492T AT 00911492 T AT00911492 T AT 00911492T AT E397014 T1 ATE397014 T1 AT E397014T1
Authority
AT
Austria
Prior art keywords
hiv
antigens
peptides
vaccine compositions
hiv peptides
Prior art date
Application number
AT00911492T
Other languages
English (en)
Inventor
Birger Soerensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Application granted granted Critical
Publication of ATE397014T1 publication Critical patent/ATE397014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
AT00911492T 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen ATE397014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Publications (1)

Publication Number Publication Date
ATE397014T1 true ATE397014T1 (de) 2008-06-15

Family

ID=19903050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911492T ATE397014T1 (de) 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen

Country Status (23)

Country Link
US (4) US6706859B1 (de)
EP (1) EP1159298B1 (de)
JP (5) JP2002541069A (de)
CN (4) CN101328209A (de)
AT (1) ATE397014T1 (de)
AU (1) AU771827B2 (de)
BR (1) BR0008741A (de)
CA (1) CA2363947C (de)
CY (1) CY1108299T1 (de)
CZ (1) CZ300505B6 (de)
DE (1) DE60039036D1 (de)
DK (1) DK1159298T3 (de)
EA (1) EA004802B9 (de)
ES (1) ES2307496T4 (de)
HK (1) HK1044778B (de)
HU (1) HU229282B1 (de)
ID (1) ID30497A (de)
NO (1) NO311807B1 (de)
NZ (4) NZ514619A (de)
PT (1) PT1159298E (de)
SK (1) SK287382B6 (de)
WO (1) WO2000052040A1 (de)
ZA (1) ZA200107072B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503205A (ja) 2000-02-04 2004-02-05 デューク・ユニバーシティー ヒト免疫不全ウイルスワクチン
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
ES2616341T3 (es) 2006-03-10 2017-06-12 Peptcell Limited Péptidos de proteínas reguladoras o accesorias de VIH, composiciones y la utilización de las mismas
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
EP2646459B1 (de) * 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (de) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Verfahren und zusammensetzungen für therapeutika
IN2014KN02769A (de) * 2012-06-06 2015-05-08 Bionor Immuno As
AU2013273481B2 (en) 2012-06-06 2018-04-05 Bionor Immuno As HIV vaccine
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3033106A1 (de) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunadjuvanzienzusammensetzungen und verwendungen davon
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
CA2936335A1 (en) 2014-01-27 2015-07-30 Bionor Immuno As Dosage regimen for hiv vaccine
EP3099322A1 (de) 2014-01-27 2016-12-07 Bionor Immuno AS Verfahren zur impfung gegen hiv
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
RS60187B1 (sr) * 2014-04-03 2020-06-30 Amgen Inc Metoda za pripremanje amg 416
WO2016005508A1 (en) 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016177833A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6713287A (en) 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
JP2634203B2 (ja) 1987-09-04 1997-07-23 インターナショナル ミュレックス テクノロジーズ コーポレイション イムノアツセイおよびそれに使用される生物学的構築体
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
EP0356007A3 (de) 1988-07-22 1991-07-03 Medical Research Council Antigenische Determinanten
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) * 1993-03-31 1996-09-06 Fernand Narbey Torossian Complexe immunomodulateur anti SIDA.
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
ATE228248T1 (de) * 1997-03-10 2002-12-15 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv- antigenen und hiv-antikörpern

Also Published As

Publication number Publication date
NZ525753A (en) 2004-10-29
JP5695010B2 (ja) 2015-04-01
JP2013032384A (ja) 2013-02-14
JP2014043468A (ja) 2014-03-13
JP5695012B2 (ja) 2015-04-01
HK1044778A1 (en) 2002-11-01
CN101328210A (zh) 2008-12-24
EA004802B1 (ru) 2004-08-26
DE60039036D1 (de) 2008-07-10
JP5313998B2 (ja) 2013-10-09
NO991078D0 (no) 1999-03-04
HK1044778B (zh) 2009-04-24
JP5814331B2 (ja) 2015-11-17
SK287382B6 (sk) 2010-08-09
ZA200107072B (en) 2002-11-27
CN101328209A (zh) 2008-12-24
DK1159298T3 (da) 2008-08-25
CA2363947A1 (en) 2000-09-08
ES2307496T4 (es) 2015-03-06
BR0008741A (pt) 2002-01-08
NZ525751A (en) 2004-10-29
JP2013032386A (ja) 2013-02-14
AU3335800A (en) 2000-09-21
NO311807B1 (no) 2002-01-28
US20080107669A1 (en) 2008-05-08
CN101328208A (zh) 2008-12-24
EA200100943A1 (ru) 2002-02-28
HU229282B1 (en) 2013-10-28
CN100387617C (zh) 2008-05-14
CN1346367A (zh) 2002-04-24
PT1159298E (pt) 2008-09-04
ID30497A (id) 2001-12-13
NZ514619A (en) 2003-10-31
CZ300505B6 (cs) 2009-06-03
US7709003B2 (en) 2010-05-04
ES2307496T3 (es) 2008-12-01
US7709004B2 (en) 2010-05-04
US20040259797A1 (en) 2004-12-23
AU771827B2 (en) 2004-04-01
JP2002541069A (ja) 2002-12-03
NZ525752A (en) 2004-10-29
US7311915B2 (en) 2007-12-25
SK12402001A3 (sk) 2002-02-05
EA004802B9 (ru) 2015-03-31
CY1108299T1 (el) 2014-02-12
EP1159298B1 (de) 2008-05-28
NO991078L (no) 2000-09-05
CA2363947C (en) 2008-05-20
WO2000052040A1 (en) 2000-09-08
CZ20013195A3 (cs) 2002-02-13
US6706859B1 (en) 2004-03-16
JP2011074081A (ja) 2011-04-14
EP1159298A1 (de) 2001-12-05
HUP0200265A2 (en) 2002-06-29
US20080107670A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
Gilljam Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DE60037450D1 (de) Funf-helix protein
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
EP1016671A3 (de) Menschliche, monoklonale Antikörper gegen das transmembrane Glycoprotein (gp41) des HIV-1, und verwandte Peptide
Kennedy et al. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.
DE60044259D1 (de) HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER
Lizeng et al. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
Benjamini et al. Isolation and characterization of the neutralizable epitope of simian retrovirus-1 (SRV-1) and of the cell receptor for the virus
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
FR2874017B1 (fr) Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
ATE122236T1 (de) Vorläufer des hüllenglykoproteins des hiv-2 retrovirus und verwandte antigene.
TH62264A (th) Hiv เพพไทด์, แอนติเจน องค์ประกอบวัคซีน, ชุดสำเร็จรูปอิมมูโนแอสเสย์ และวิธีสำหรับตรวจหาแอนติบอดีที่ชักนำโดย hiv
Gnann Jr et al. Designing Peptides to Immunologically Distinguish Specific Human Immunodeficiency Virus Isolates

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1159298

Country of ref document: EP